Quince Therapeutics (QNCX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Quince Therapeutics (QNCX) is Moderate Underperform.

The composite score behind that read is -0.39, weighing +0.21 of bullish evidence against -0.44 bearish.

Quince Therapeutics last closed at $28.10, -3.77% on the session.

Against the IVW growth benchmark the position is -4.69% over the forecast window.

The read is built from 13 underlying insights — 2 bullish and 11 bearish.

Agreement across those insights is 85%.

16 graded predictions for QNCX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Quince Therapeutics in the 99th percentile on return on equity, where 100 is best.

Quince Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $29.70M.

StockMap tracks Quince Therapeutics as the 295th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Quince Therapeutics ranks 310th of 344 in the group, against a group median of -0.21.